Our story

Tissue reconstruction

TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function.

Potential

Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas.

Modular approach

Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices.

Integrated platform

We have developed a fully integrated innovation, design, commercialization and manufacturing platform to support our internal programs as well as co-development partnerships with leaders in the medtech industry.

Timeline

2013

  • TISSIUM is founded

2014

  • Technology transfer of our first polymer: PGSA
  • Publication featuring the TISSIUM platform in Science Translational Medicine

2015

  • Design of our first accesories
  • ISO certification of TISSIUM

2016

  • Blue Seal clinical trial completed
  • TISSIUM platform expansion to new surgical fields

2017

  • First CE Mark granted for vascular sealant
  • TISSIUM platform expansion to 3D printing

2018

  • ISO certification of manufacturing facility in Roncq, France

2019

  • TISSIUM platform expansion to peripheral nerve repair

2020

  • TISSIUM platform expansion into drug delivery
  • CE Mark granted for vascular sealant in pre-filled syringe format

Meet our leadership team

Management

Christophe Bancel

Christophe Bancel

Co-Founder,
Chief Executive Officer

Christophe Bancel is Co-founder and CEO of TISSIUM. Prior to founding the company, he has held corporate and strategic leadership positions at UCB and Serono and was Co-founder and Business Development Director at Domain Therapeutics. Christophe holds a MSc in Engineering from Ecole Centrale Paris, a MSc in Molecular Biology from the University of Tokyo, and an MBA from INSEAD.

Maria Pereira

Maria Pereira

Co-Founder,
Chief Innovation Officer

Maria Pereira leads the Innovation Hub at TISSIUM. She co-invented the technology while a PhD student at Prof. Jeff Karp’s Laboratories. She has been recognized for her research by MIT Tech Review’s “35 Innovators Under 35” in 2014, as well as Forbes in its “30 under 30” selection in Healthcare in 2015. Maria holds a PhD in Bioengineering from the MIT-Portugal program and an MBA from INSEAD.

Youssef Biadillah

Youssef Biadillah

Chief Development Officer

Youssef Biadillah leads the Development Factory at TISSIUM. He has over 15 years of experience in leadership and product development roles at early-stage medtech companies, including Baylis Medical, Sadra Medical, and Symetis, and was co-founder of Anchor Orthopedics and AboGen. Youssef holds a BSc in Mechanical Engineering and a MSc in Biomedical Engineering, both from McGill University.

Brice Epry

Brice Epry

Chief of Staff

Brice Epry leads TISSIUM’s Corporate, Finance, Human Resources and General Administration activities. He has over 15 years of experience in cross-functional roles at medium and large companies including Distrilogie, Eurovia and UCB. During his tenure at UCB, Brice held leadership roles in Controlling, Business Intelligence, and Brand Management. Brice holds a BSc in Business Administration from EDC Paris Business School with a specialization in Finance.

Board members

Jay Watkins

Jay Watkins

Chairman of the Board,
Independent Director

Christophe Bancel

Christophe Bancel

Co-Founder,
Chief Executive Officer

Antoine Papiernik

Antoine Papiernik

Representative
Sofinnova Partners

Jean-François Morin

Jean-François Morin

Representative
Bpifrance

Karine Lignel

Karine Lignel

Representative
CM – CIC Innovation

Walid Sfeir

Walid Sfeir

Representative
Valquest Partners

Jeff Karp

Jeff Karp

Co-Founder and Observer